Flavopiridol displays preclinical activity in acute lymphoblastic leukemia

Pediatric Blood and Cancer

Volumn 50, Issue 4, 2008, Pages 772-778

  Jackman, Kelly M ^a   Frye, Carole B ^a   Hunger, Stephen P ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b Box B115 ^*  (United States)

Author keywords

Acute lymphoblastic leukemia; Cell cycle; Flavopiridol; Relapse; Treatment

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; FLAVOPIRIDOL; PROTEIN MCL 1; RETINOBLASTOMA PROTEIN; RNA POLYMERASE II; SERINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RELAPSE; CARBOXY TERMINAL SEQUENCE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; SERUM;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; FLAVONOIDS; HUMANS; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; PIPERIDINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTO-ONCOGENE PROTEINS C-BCL-2; RETINOBLASTOMA PROTEIN; RNA POLYMERASE II;

EID: 40449099701     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21386     Document Type: Article

References (41)

1. Gaynon PS, Qu RP, Chappell RJ, et al. Survival after relapse in childhood acute lymphoblastic leukemia. Cancer 1998;82:1387-1395.
2. Lawson SE, Harrison G, Richards S, et al. The UK experience in treating relapsed childhood acute lymphoblastic leukaemia: A report on the medical research council UKALLR1 study. Br J Haematol 2000;108:531-543.
3. Rivera GK, Zhou Y, Hancock ML, et al. Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia. Cancer 2005;103:368-376.
4. ink4b gene abnormalities between initial diagnosis and relapse in children with acute lymphoblastic leukemia. Blood 1999;93:2380-2385.
5. Carter TL, Reaman GH, Kees UR. INK4A/ARF deletions acquired at relapse in childhood acute lymphoblastic leukemia: A paired study on 25 patients using real-time polymerase chain reaction. Br J Haematol 2001;113:323-328.
6. Sherr CJ. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2001;2:731-737.
7. Bhojwani D, Kang H, Moskowitz NP, et al. Biological pathways associated with relapse in childhood acute lymphoblastic leukemia: A children's oncology group study. Blood 2006;108:711-717.
8. Sedlacek HH. Mechanisms of action of flavopiridol. Crit Rev Oncol Hematol 2001;38:139-170.
9. Chao SH, Fujinaga K, Marion JE, et al. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J Biol Chem 2000;275:28345-28348.
10. Chao SH, Price DH. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem 2001;276:31793-31799.
11. Lam LT, Pickeral OK, Peng AC, et al. Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol 2001;2:research 0041.1-research 0041.11.
12. Chen R, Keating MJ, Gandhi V, et al. Transcriptional inhibition by flavopiridol: Mechanism of chronic lymphocytic leukemia cell death. Blood 2005;106:2513-2519.
13. Kaur G, Stetler-Stevenson M, Sebers S, et al. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J Natl Cancer Inst 1992;84:1736-1740.
14. Semenov I, Akyuz C, Roginskaya V, et al. Growth inhibition and apoptosis of myeloma cells by the CDK inhibitor flavopiridol. Leuk Res 2002;26:271-280.
15. Liesveld JL, Abboud CN, Lu C, et al. Flavonoid effects on normal and leukemic cells. Leuk Res 2003;27:517-527.
16. Parker BW, Kaur G, Nieves-Neira W, et al. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood 1998;91:458-465.
17. Pepper C, Thomas A, Hoy T, et al. Flavopiridol circumvents bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukaemia. Br J Haematol 2001;114:70-77.
18. Karp JE, Passaniti A, Gojo I, et al. Phase I and pharmacokinetic study of flavopiridol followed by 1-β-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. Clin Cancer Res 2005;11:8403-8412.
19. Minowada J, Tsubota T, Nakazawa S, et al. Establishment and characterization of leukemic T-cell lines, B-cell lines and null-cell lines: A progress report on surface antigen study of fresh lymphatic leukemias in man. In: Thierfelder S, Rodt H, Thiel E, editors. Immunological diagnosis of leukemias and lymphomas. Berlin, Heidelberg, New York: Springer-Verlag 1977. p 241.
20. Jack I, Seshadri R, Garson M, et al. RCH-ACV: A lymphoblastic leukemia cell line with chromosome translocation 1;19 and trisomy 8. Cancer Genet Cytogenet 1986;19:261-269.
21. Pieters R, Loonen AH, Huismans DR, et al. In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions. Blood 1990;76:2327-2336.
22. Guo S-X, Taki T, Ohnishi H, et al. Hypermethylation of p16 and p15 genes and RB protein expression in acute leukemia. Leuk Res 2000;24:39-46.
23. Ormerod MG. Analysis of DNA-general methods. In: Ormerod MG, editor. Flow cytometry-practical approach. Oxford: Oxford University Press 2000. pp 83-97.
24. Kawamura M, Ohnishi H, Guo S-X, et al. Alteration of the p53, p21, p15, and RAS genes in childhood T-cell acute lymphoblastic leukemia. Leuk Res 1999;23:115-126.
25. Drexler H. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18, and p19 in human leukemia-lymphoma cells. Leukemia 1998;12:845-859.
26. inka/CDKN2 gene in leukaemic cell lines inhibits cell proliferation. Br J Haematol 1996;95:291-298.
27. ink4b deletions in childhood acute lymphoblastic leukemias containing distinct E2A translocations. Leukemia 1998;12:1417-1421.
28. Shapiro GI, Supko JG, Patterson A, et al. A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. Clin Cancer Res 2001;7:1590-1599.
29. Senderowicz AM, Headlee D, Stinson SF, et al. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 1998;16:2986-2999.
30. Tan AR, Headlee D, Messmann R, et al. Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J Clin Oncol 2002;20:4074-4082.
31. Thomas JP, Tutsch KD, Cleary JF, et al. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. Cancer Chemother Pharmacol 2002;50:465-472.
32. Rudek MA, Bauer KSJ, Lush RM, et al. Clinical pharmacology of flavopiridol following a 72-hour continuous infusion. Ann Pharmacother 2003;37:1369-1374.
33. Zhai S, Sausville EA, Senderowicz AM, et al. Clinical pharmacology and pharmcogenetics of flavopiridol 1-h i.v. infusion in patients with refractory neoplasms. Anti-Cancer Drugs 2003;14:125-135.
34. Connell-Crowley L, Harper JW, Goodrich DW. Cyclin D1/CDK4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. Mol Biol Cell 1997;8:287-301.
35. 1-S cyclin-dependent kinases. J Biol Chem 1997;272:12738-12746.
36. Byrd JC, Peterson BL, Gabrilove J, et al. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: Results from Cancer and Leukemia Group B study 19805. Clin Cancer Res 2005;11:4176-4181.
37. Byrd JC, Lin TS, Dalton JT, et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high risk chronic lymphocytic leukemia. Blood 2007;109:399-404.
38. Adams PD. Regulation of the retinoblastoma tumor suppressor protein by cyclin/CDKs. Biochim Biophys Acta 2001; 1471:M123-M133.
39. Aklilu M, Kindler HL, Donehower RC, et al. Phase II study of flavopiridol in patients with advanced colorectal cancer. Ann Oncol 2003;14:1270-1273.
40. Schwartz GK, Ilson D, Saltz L, et al. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J Clin Oncol 2001;19:1985-1992.
41. Stadler WM, Vogelzang NJ, Amato R, et al. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: A University of Chicago Phase II Consortium study. J Clin Oncol 2000;18:371-375.